Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Electrocardiographic left ventricular hypertrophy predicts arrhythmia and mortality in patients with ischemic cardiomyopathy.

Bender SR, Friedman DJ, Markowitz SM, Lerman BB, Okin PM.

J Interv Card Electrophysiol. 2012 Sep;34(3):237-45. doi: 10.1007/s10840-011-9661-2.

PMID:
22354775
2.

T-wave alternans and ST depression assessment identifies low risk individuals with ischemic cardiomyopathy in the absence of left ventricular hypertrophy.

Friedman DJ, Bender SR, Markowitz SM, Lerman BB, Okin PM.

Ann Noninvasive Electrocardiol. 2013 Jul;18(4):359-68. doi: 10.1111/anec.12051.

PMID:
23879276
3.

Comparison of ventricular tachyarrhythmia characteristics in patients with idiopathic dilated or ischemic cardiomyopathy and defibrillators implanted for primary prevention.

Streitner F, Kuschyk J, Dietrich C, Mahl E, Streitner I, Doesch C, Veltmann C, Schimpf R, Wolpert C, Borggrefe M.

Clin Cardiol. 2011 Oct;34(10):604-9. doi: 10.1002/clc.20949.

4.

T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy.

Rosenthal TM, Stahls PF 3rd, Abi Samra FM, Bernard ML, Khatib S, Polin GM, Xue JQ, Morin DP.

Heart Rhythm. 2015 Aug;12(8):1789-97. doi: 10.1016/j.hrthm.2015.04.035.

PMID:
25998895
5.

Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.

Okin PM.

J Electrocardiol. 2009 Nov-Dec;42(6):584-8. doi: 10.1016/j.jelectrocard.2009.06.020.

PMID:
19631946
6.

Association between statin use and mortality in patients with implantable cardioverter-defibrillators and left ventricular systolic dysfunction.

Coleman CI, Kluger J, Bhavnani S, Clyne C, Yarlagadda R, Guertin D, White CM.

Heart Rhythm. 2008 Apr;5(4):507-10. doi: 10.1016/j.hrthm.2007.12.023.

PMID:
18362016
7.

Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study.

Klein G, Lissel C, Fuchs AC, Gardiwal A, Oswald H, Desousa M, Pichlmaier AM, Lichtinghagen R, Geerlings H, Lippolt P, Niehaus M, Drexler H, Korte T.

Europace. 2006 Aug;8(8):618-24.

8.
9.

QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.

Haigney MC, Zareba W, Gentlesk PJ, Goldstein RE, Illovsky M, McNitt S, Andrews ML, Moss AJ; Multicenter Automatic Defibrillator Implantation Trial II investigators..

J Am Coll Cardiol. 2004 Oct 6;44(7):1481-7.

10.

Predicting ventricular arrhythmias in patients with ischemic heart disease: clinical application of the ECG-derived QRS-T angle.

Borleffs CJ, Scherptong RW, Man SC, van Welsenes GH, Bax JJ, van Erven L, Swenne CA, Schalij MJ.

Circ Arrhythm Electrophysiol. 2009 Oct;2(5):548-54. doi: 10.1161/CIRCEP.109.859108.

11.

Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).

Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ; MADIT-II Investigators..

J Am Coll Cardiol. 2005 Nov 1;46(9):1712-20.

12.

Long-term follow-up in patients with arrhythmogenic right ventricular cardiomyopathy.

Li CH, Lin YJ, Huang JL, Wu TJ, Cheng CC, Lin WS, Tuan TC, Chang SL, Lo LW, Hu YF, Chao TF, Chung FP, Tsai CF, Tsao HM, Chen SA.

J Cardiovasc Electrophysiol. 2012 Jul;23(7):750-6. doi: 10.1111/j.1540-8167.2011.02288.x.

PMID:
22353378
13.

Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.

Evonich RF, Maheshwari A, Gardiner JC, Khasnis A, Kantipudi S, Ip JH, Grimes D, Hayter G, Thakur RK.

J Interv Card Electrophysiol. 2004 Aug;11(1):59-65.

PMID:
15273456
14.

The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.

Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):739-47. doi: 10.1161/CIRCEP.112.970566.

15.

Fragmented QRS and mortality risk in patients with left ventricular dysfunction.

Cheema A, Khalid A, Wimmer A, Bartone C, Chow T, Spertus JA, Chan PS.

Circ Arrhythm Electrophysiol. 2010 Aug;3(4):339-44. doi: 10.1161/CIRCEP.110.940478.

16.
17.

Risk of mortality for ventricular arrhythmia in ambulatory LVAD patients.

Brenyo A, Rao M, Koneru S, Hallinan W, Shah S, Massey HT, Chen L, Polonsky B, McNitt S, Huang DT, Goldenberg I, Aktas M.

J Cardiovasc Electrophysiol. 2012 May;23(5):515-20. doi: 10.1111/j.1540-8167.2011.02223.x.

PMID:
22081967
18.

Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.

Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.

J Am Coll Cardiol. 1999 May;33(6):1596-601.

19.

Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy.

Sesselberg HW, Moss AJ, McNitt S, Zareba W, Daubert JP, Andrews ML, Hall WJ, McClinitic B, Huang DT; MADIT-II Research Group..

Heart Rhythm. 2007 Nov;4(11):1395-402.

PMID:
17954398
20.

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators..

Ann Intern Med. 2007 Sep 4;147(5):311-9.

PMID:
17785486
Items per page

Supplemental Content

Support Center